Zelira Therapeutics (QB) Stock Price - ZLDAF

0.004 (9.76%)
Best deals to access real time data!
Small Cap Pro
Monthly Subscription
for only
Canna Trader Pro
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Zelira Therapeutics Ltd (QB) ZLDAF OTCMarkets Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
0.004 9.76% 0.045 0.04 0.0469 0.04125 0.041 16:30:31
Bid Price Ask Price Spread Spread % News
0.038 0.0497 0.0117 23.54% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
38 762,500 $ 0.041541 $ 31,675 232,962 0.0179 - 0.079
Last Trade Time Type Quantity Stock Price Currency
15:57:11 50,000 $ 0.045 USD

Zelira Therapeutics (QB) Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 39.26M 872.44M 755.34M $ - $ - - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
168.34k $ - 0.00% - -

more financials information »

Zelira Therapeutics (QB) News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ZLDAF Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.0350.0510.0310.0368451226,9850.0128.57%
1 Month0.0360.0510.02720.033323317,1560.00925.0%
3 Months0.03130.0510.01790.0313563221,6030.013743.77%
6 Months0.0470.0590.01790.0329627156,164-0.002-4.26%
1 Year0.032950.0790.01790.040619135,3350.0120536.57%
3 Years0.0590.1510.01790.066087134,537-0.014-23.73%
5 Years0.040.1510.01790.0671722132,7350.00512.5%

Zelira Therapeutics (QB) Description

Zelira Therapeutics ("Zelira") is an Australian-based bio-pharmaceutical company that is focused on developing a range of cannabinoid-based formulations for the treatment of a variety of medical conditions. The Company has a two-pronged strategy comprising: A human clinical trial programme focused on insomnia, autism and eczema with activities in Australia and Chile. A pre-clinical research programme examining the effect of cannabinoids in breast, brain and pancreatic cancer. It has partnered with the world's leading cancer cannabis researchers at Complutense University Madrid in Spain to conduct certain pre-clinical work testing cannabis-based formulations known to have an effect in humans in order to generate data packs in a form expected by regulators and the pharmaceutical industry. A similar programme is in place with the Australian Telethon Kids Institute targeting paediatric brain cancer and Curtin University targeting pancreatic cancer.

Your Recent History
Zelira The..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.